FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
March 11, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology...
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024 16:06 ET
|
FibroGen, Inc.
• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate...
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
February 26, 2024 16:05 ET
|
FibroGen, Inc.
The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen,...
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close....
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
February 05, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM...
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
January 25, 2024 07:00 ET
|
FibroGen, Inc.
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated patients is anticipated in 2Q 2024Pamrevlumab is the first experimental arm...
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
December 09, 2023 17:02 ET
|
FibroGen, Inc.
please call Meichiel Keenan@650-219-6482 with any questions.
FibroGen Reports Third Quarter 2023 Financial Results
November 06, 2023 16:01 ET
|
FibroGen, Inc.
Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in...
FibroGen to Report Third Quarter 2023 Financial Results
October 23, 2023 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also...
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
August 29, 2023 16:15 ET
|
FibroGen, Inc.
– Study did not meet the primary endpoint – – Pamrevlumab was generally safe and well tolerated – SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced...